Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer

Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer

David R. Jones, MD, and Roy S. Herbst, MD, PhD, discuss lung cancer in this CME activity titled "Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer." For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ZUJ865. CME credit will be available until November 9, 2021.